Tacrolimus: Nursing Drug Guide, Nephrotoxicity & Trough Monitoring
Tacrolimus prevents organ rejection in kidney, liver, heart, and lung transplant patients, but the bedside safety story is nephrotoxicity + trough monitoring + formulation accuracy. A supratherapeutic level after a CYP3A4 inhibitor, an immediate-release versus extended-release swap, or overlapping cyclosporine without washout can push creatinine up fast—while missed infection cues under immunosuppression can be equally dangerous.
Prograf labeling carries a boxed warning for increased susceptibility to serious infection and malignancy (including lymphoma). Tacrolimus also causes dose-related nephrotoxicity—rising serum creatinine, oliguria, and hyperkalemia may be early toxicity cues. Immediate-release Prograf is not interchangeable with extended-release tacrolimus (Astagraf XL, Envarsus XR). Do not give with cyclosporine—wash out at least 24 hours before switching calcineurin inhibitors.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every tacrolimus dose: confirm immediate-release vs extended-release product, verify the latest whole-blood trough and creatinine trend, reconcile CYP3A4 inhibitors/inducers and nephrotoxic drugs, and hold when levels or renal function cross protocol limits. Teach patients to report fever, less urine, tremor, and new neurologic symptoms immediately—and to avoid grapefruit and live vaccines unless the team directs otherwise.
Most common brand names
Generic: tacrolimus (FK506). Systemic transplant products differ by release mechanism—never assume brands or strengths are interchangeable.
Common brands (systemic transplant): Prograf (immediate-release capsules, injection, granules for oral suspension), Astagraf XL (extended-release), Envarsus XR (extended-release). Topical tacrolimus (e.g., Protopic) treats atopic dermatitis at much lower exposure—do not confuse with transplant systemic dosing.
Why we give it — Indications
Per Prograf prescribing information, tacrolimus is indicated for prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic transplants, in combination with other immunosuppressants, under physicians experienced in immunosuppressive therapy with adequate laboratory support.
| Use (Prograf labeling) | Nursing relevance |
|---|---|
| Kidney transplant rejection prophylaxis | Whole-blood trough monitoring; early post-transplant nephrotoxicity surveillance |
| Liver transplant rejection prophylaxis | Monitor glucose for new-onset diabetes after transplant; neurotoxicity/PRES vigilance |
| Heart transplant rejection prophylaxis | Lower initial doses in labeling; avoid sirolimus combination per warnings |
| Lung transplant rejection prophylaxis | Specialist-managed dosing with protocol-specific trough targets |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tacrolimus binds FKBP-12 and inhibits calcineurin, blocking IL-2 transcription and T-cell activation. This suppresses cell-mediated immunity to prevent graft rejection. Whole-blood trough concentrations correlate with exposure but assay method and formulation affect reported values—nurses protect patients by timing trough draws, catching interactions, and escalating renal or neurologic trends, not by adjusting doses independently.
Onset, peak, duration, half-life
| Parameter | Value (Prograf labeling) | Nursing relevance |
|---|---|---|
| Tmax (oral) | Approximately 1.5–2.1 hours (varies by transplant population) | Take consistently with respect to meals; high-fat meals decrease absorption |
| Half-life (oral) | Approximately 48 hours based on tacrolimus concentrations in healthy volunteers | Steady state and trough timing need several days; missed doses affect levels slowly but significantly |
| Half-life (IV, pediatrics) | Labeling reports ~10–12 hours in pediatric transplant studies | Pediatric patients often need different mg/kg doses to reach similar troughs |
| Duration | Chronic immunosuppression—continuous therapy | Do not stop abruptly without prescriber direction—rejection risk |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Institutional transplant protocols vary. Verify every order against current Prograf prescribing information, prescriber plan, and local trough targets.
Prograf immediate-release capsules/granules and extended-release products (Astagraf XL, Envarsus XR) are not substitutable mg-for-mg. Changes between formulations require prescriber supervision and intensified trough monitoring.
Renal/hepatic impairment, Black transplant patients (labeling notes may need higher doses), and cystic fibrosis (lower bioavailability) may alter exposure—pharmacy and prescriber adjust per protocol.
Trough targets are transplant type, time-from-transplant, and protocol specific—do not use a single target range universally. The 7–20 ng/mL examples in labeling apply only to the cited kidney-transplant scenario.
Common nursing error: confusing Prograf, Astagraf XL, and Envarsus XR
Immediate-release Prograf capsules/granules are not interchangeable with extended-release Astagraf XL or Envarsus XR because absorption differs—mg-for-mg substitution without prescriber supervision can cause underexposure (rejection) or overexposure (nephrotoxicity). Verify NDC, capsule appearance, and MAR product name on every dose; intensify trough and creatinine monitoring after any formulation change.
Before you give it — Safety check
Pretreatment checks
- Confirm exact product on MAR: immediate-release (Prograf capsules/granules) vs extended-release (Astagraf XL, Envarsus XR) and oral vs IV route
- Review latest tacrolimus trough/C0 and trend of BMP including creatinine and potassium
- Measure or review blood pressure; screen for hypertension symptoms
- Reconcile nephrotoxic and CYP3A4-interacting drugs (gentamicin, amphotericin B, ketoconazole, rifampin, prednisone combinations per labeling)
- Screen for active infection (fever, dysuria, cough) and recent live-vaccine plans
- Verify patient avoids grapefruit/grapefruit juice and maintains consistent dosing schedule with meals
Contraindications (Prograf labeling)
- Hypersensitivity to tacrolimus
- Prograf injection: hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil)
Critical interaction — cyclosporine overlap
Prograf should not be used simultaneously with cyclosporine. Discontinue cyclosporine at least 24 hours before initiating tacrolimus; if either drug level is elevated, further delay the switch per labeling.
Key interactions — intensify monitoring
| Interaction | Clinical concern | Nursing action |
|---|---|---|
| Nephrotoxic drugs (aminoglycosides, amphotericin, NSAIDs) | Additive renal injury | Increase creatinine/trough surveillance; hold and notify if renal function worsens |
| Strong CYP3A4 inhibitors (azole antifungals, macrolides, HIV protease inhibitors) | Higher tacrolimus exposure | Anticipate trough review after any new inhibitor starts |
| CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) | Lower exposure—rejection risk | Do not stop inducer without prescriber plan; verify levels after changes |
| Grapefruit juice | Increased blood concentration | Teach avoidance; document dietary counseling |
| Prednisone / other immunosuppressants | Increased infection and malignancy risk | Infection screen every contact; avoid live vaccines |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral immediate-release (Prograf capsules/granules): May be taken with or without food, but food affects bioavailability—take consistently the same way each dose. High-fat meals decrease absorption per labeling.
- Swallow capsules whole unless specific product instructions allow opening; granules mixed per pharmacist directions
- Draw trough specimens at consistent timing relative to dose (typically pre-dose / 12 h post-dose per protocol)
- IV Prograf: continuous infusion only; observe first 30 minutes for anaphylaxis; convert to oral when tolerated
- Have epinephrine and oxygen available during IV initiation per labeling
Prograf capsules/granules are not interchangeable with Astagraf XL or Envarsus XR. Under- or overexposure from formulation errors can cause graft rejection or nephrotoxicity—verify NDC and capsule appearance every time.
Expected therapeutic response
- Transplant: stable graft function with target trough range and no rejection signs (protocol-defined)
- Rheumatoid arthritis: reduced joint swelling, pain, and morning stiffness over weeks
- Psoriasis: improved plaque thickness and body-surface involvement when renal function remains acceptable
- Lack of improvement or rising creatinine should trigger prescriber/pharmacy review—not silent dose continuation
Red flags — Stop and act
Immunosuppression plus nephrotoxicity means early escalation saves kidneys and grafts.
- Oliguria, rapid creatinine rise, or BUN/creatinine pattern suggesting toxicity vs rejection—notify transplant/renal team same day
- Supratherapeutic trough with tremor, headache, or confusion—possible neurotoxicity or PRES; hold and clarify dose
- Severe hypertension, headache, visual changes, or seizure—consider PRES per labeling; emergency evaluation
- Jaundice, dark urine, or marked transaminase rise—hepatotoxicity pathway
- Sepsis signs, opportunistic infection, or new neurologic deficits (PML concern in labeling)
- Anaphylaxis or angioedema after dose
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nephrotoxicity (creatinine/BUN rise, structural kidney injury) | Boxed warning; dose- and duration-related | Trend renal labs; dose reduction/discontinuation per protocol; differentiate from rejection with team |
| Hypertension | Common; may persist | Monitor BP; avoid potassium-sparing diuretics per labeling; notify if uncontrolled |
| Hyperkalemia / hyperuricemia | Occasional | Review BMP potassium; coordinate management with prescriber |
| Hepatotoxicity (elevated enzymes, jaundice, liver failure reports) | Labeled warning; higher early post-transplant | Monitor LFTs; stop and escalate for symptomatic hepatitis pattern |
| Neurotoxicity (tremor, paresthesia, seizure, PRES) | Labeled warning | Assess neurologic status; hold and notify for new severe symptoms |
| Infection and malignancy (including skin cancers) | Boxed warning for immunosuppression | Infection vigilance; sun protection teaching; report new masses or B symptoms |
| New-onset diabetes after transplant (hyperglycemia) | Labeled warning | Monitor blood glucose; coordinate insulin or oral agents per endocrine/transplant team |
| Hyperglycemia / tremor / headache | Common; may reflect level or toxicity | Assess glucose and neurologic status; correlate with trough when available |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Prograf overdosage experience is limited. Acute overdosages up to about 30 times the intended dose have been reported, with most cases asymptomatic and full recovery. Occasional reports include transient urticaria and lethargy.
Overdose management (labeling)
- No specific antidote is listed—management is supportive and symptomatic
- Oral activated charcoal has been reported; experience is insufficient to recommend routinely
- Tacrolimus is poorly dialyzable; charcoal hemoperfusion clearance is limited
- Monitor renal function, glucose, neurologic status, and blood pressure during supportive care
- Contact local poison control or medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Prograf (immediate-release) vs Astagraf XL / Envarsus XR (extended-release)—verify NDC and capsule appearance before every dose
- Tacrolimus vs cyclosporine—both calcineurin inhibitors with different trough targets; require ≥24 h washout when switching
- Systemic vs topical Protopic—topical atopic dermatitis orders are not transplant doses
- Strength confusion—capsules 0.5, 1, and 5 mg; confirm mg on MAR and label
- Duplicate immunosuppression—MAR may list tacrolimus plus cyclosporine during protocol transitions; hold and clarify
- IV vs oral—ensure only one route is active unless prescriber orders overlap during conversion
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Do not crush or open Prograf capsules unless product-specific guidance allows; extended-release capsules must be swallowed whole |
| Food timing | Take consistently with respect to meals; high-fat meals lower absorption |
| Grapefruit | Avoid grapefruit and grapefruit juice (raises concentrations) |
| Oral solution | Mix with orange or apple juice at room temperature; rinse cup; avoid milk for Prograf solution |
| Missed dose | Not specified in the reviewed prescribing information for a universal rule—follow prescriber and transplant protocol |
| Commonly missed | Assuming pharmacy substitution is equivalent; skipping trough draw before morning dose |
| Ask pharmacy when | Any formulation change, interacting drug starts, supratherapeutic trough, or pump-controlled IV rate questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Labeling advises particular renal monitoring because age-related renal decline increases toxicity risk |
| Transplant recipients on multiple immunosuppressants | Higher infection and malignancy risk; lower threshold to hold for fever or localizing infection |
| Chronic kidney disease / prior nephrotoxic exposure | May tolerate lower doses; earlier creatinine thresholds for hold |
| Pregnancy | Prograf can cause fetal harm; labeling reports neonatal hyperkalemia and renal dysfunction; pregnancy registry available—specialist team balances risks |
| Lactation | LactMed notes low breastmilk levels with probably safe systemic use under monitoring; exclusively breastfed infants may need surveillance per specialist guidance |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal: serum creatinine, BUN, urine output trends per transplant protocol
- Cardiovascular: blood pressure at each visit; electrolytes including potassium and magnesium
- Hepatic: bilirubin, AST/ALT per protocol
- Immunosuppression labs: tacrolimus trough (and protocol-specific peaks) in transplant patients; periodic levels in RA when ordered
- Metabolic: lipids, uric acid as ordered
- Clinical: infection symptoms, neurologic changes (tremor, vision, confusion), graft tenderness or urine output change in transplant patients
Document
- Exact product (immediate-release vs extended-release), dose, route, and consistent food timing
- Most recent trough result, assay type if known, and prescriber target range
- Creatinine percent change from baseline and hold/dose-change communications
- Patient teaching on grapefruit avoidance, infection reporting, and blood pressure self-monitoring when applicable
Patient teaching
- Take tacrolimus at the same times daily and the same way with regard to meals—do not change juice or food pattern without asking the team
- Avoid grapefruit and grapefruit juice; ask before any new medicine, herb, or NSAID
- Report decreased urine, swelling, severe headache, vision changes, tremor, fever, cough, or painful urination immediately
- Do not receive live vaccines during therapy unless the prescriber plans otherwise
- Use sun protection and report new or changing skin lesions—immunosuppression increases skin cancer risk
- Carry a medication list noting immunosuppression for dental, surgical, and emergency care
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to tacrolimus or formulation components
- Hypersensitivity to tacrolimus or HCO-60 (IV formulation)
- Formulation/product change on MAR without documented conversion plan (immediate-release ↔ extended-release)
- Cyclosporine on MAR within 24 hours of last dose without prescriber-directed switch plan
- Supratherapeutic trough or rapid creatinine rise meeting institutional/transplant hold thresholds
- Supratherapeutic trough with rising creatinine, oliguria, or hyperkalemia meeting protocol hold thresholds
- Active serious infection, suspected sepsis, or scheduled live-vaccine administration
- New nephrotoxic drug (e.g., aminoglycoside) started without updated monitoring orders
- Particulate/discolored oral solution, wrong syringe dose, or patient unable to tolerate oral intake when oral route is required
Transplant rejection vs nephrotoxicity requires specialist interpretation—holding the dose and notifying the team is appropriate when renal status acutely worsens.
Clinical practice integration and workflow
On transplant and autoimmune floors, tacrolimus safety is a systems problem: correct product, timed trough, and renal trend must align before the capsule is swallowed.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and formulation (immediate-release vs extended-release)
- Compare trough to prescriber target and check creatinine change from baseline
- Review BP and infection screen; confirm no live vaccine due
- Oral solution: correct diluent, syringe marking, and administration time vs meals
2. High-alert and safety badge
Not on all institutional high-alert lists, but behaves as narrow-index immunosuppressionTreat tacrolimus with transplant-level rigor: independent double-check on formulation switches and trough timing.
3. Clinical workflow: hold and question rules
- If supratherapeutic trough accompanies creatinine rise after a new CYP3A4 inhibitor, hold pending pharmacist review and repeat level
- If pharmacy dispensed a different tacrolimus release formulation, hold until conversion plan and extra levels are ordered
- If patient reports fever with graft pain or urine output drop, hold immunosuppression only per protocol but escalate immediately
4. Critical teach-back questions
- “What drinks or foods should you avoid with tacrolimus?” (Patient should mention grapefruit/grapefruit juice and maintaining consistent meal timing.)
- “What symptoms mean you should call before the next dose?” (Patient should include less urine, swelling, fever, severe headache, tremor, or yellowing skin.)
5. Care coordination
Pharmacist / transplant pharmacy: Trough interpretation, formulation conversion, interaction management
Prescriber / transplant or rheumatology team: Dose changes, rejection workup, and hold/resume decisions
🧠 Quick mental checklist
- Immediate-release or extended-release product—does MAR match the vial label?
- Is today's trough drawn before the morning dose when ordered?
- Creatinine trend vs baseline—hold threshold met?
- Any new nephrotoxic or CYP3A4 drug since last dose?
- Fever, dysuria, cough, or neurologic changes?
Tacrolimus NCLEX practice questions
Practice NCLEX-style clinical judgment practice for tacrolimus trough safety and nephrotoxicity using a tabbed kidney-transplant case (MAR, labs, vitals, nursing notes), then priority action, SATA cue recognition, renal trend interpretation, documentation cloze, ordered escalation steps, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Tacrolimus (Prograf) 3 mg PO BID — 0900 dose held pending trough review
- Prednisone 10 mg PO daily
- Mycophenolate mofetil 500 mg PO BID
- Ketoconazole 200 mg PO daily — started day 10 for fungal prophylaxis
- Pharmacy note: discharge list showed Astagraf XL 5 mg daily; inpatient cart has Prograf 1 mg capsules
- Baseline creatinine 1.0 mg/dL on admission
- Day 8: creatinine 1.1 mg/dL; tacrolimus trough 9 ng/mL (target 7–12 ng/mL)
- Day 12 AM: creatinine 1.7 mg/dL; BUN 42 mg/dL; K+ 5.6 mEq/L
- Day 12 trough (pre-dose): 22 ng/mL (target 7–12 ng/mL)
- Fasting glucose 198 mg/dL (was 112 mg/dL on day 8)
- BP 158/94 mmHg (baseline 128/78); HR 88; Temp 37.1 °C
- Weight up 2.1 kg since day 8; bilateral ankle edema
- Urine output last 24 h: 1180 mL (previously 2000–2300 mL/day)
- Alert; fine hand tremor; denies headache, vision changes, or dysuria
- 0840: Nurse held 0900 tacrolimus after reviewing supratherapeutic trough and new ketoconazole on MAR
- 0845: Patient asks why capsules look different from home "once-daily orange pill"
- 0855: Transplant pharmacist notified; repeat BMP and trough ordered
- 0900: Patient taught to report decreased urine, swelling, tremor, and fever promptly
Answer key & rationale
Frequently asked questions
Why are immediate-release and extended-release tacrolimus not interchangeable?
Prograf immediate-release and extended-release products (Astagraf XL, Envarsus XR) have different absorption rates. Mg-for-mg switching without prescriber supervision can cause toxicity or graft rejection.
What should I check before giving tacrolimus?
Confirm product and route, review trough and creatinine trend, blood pressure, infection symptoms, interacting drugs, and grapefruit avoidance. Draw pre-dose trough when ordered.
When should tacrolimus be held?
Hold for hypersensitivity, IV castor-oil excipient reaction, IR/ER interchange errors, supratherapeutic trough with renal rise, cyclosporine overlap, serious infection, live vaccines, or neurologic red flags—then contact prescriber/pharmacist.
Is there an antidote for tacrolimus overdose?
No specific antidote is listed. Care is supportive; gastric decontamination may help within 2 hours of oral ingestion. Contact poison control per facility protocol.
Which adverse effects matter most for nurses?
Nephrotoxicity, hypertension, hyperkalemia, hepatotoxicity, neurotoxicity (including PRES), and serious infection/malignancy risks require proactive monitoring and escalation.
Can patients breastfeed on tacrolimus?
Tacrolimus is present in human milk; no adverse infant effects are reported in available data. Weigh breastfeeding benefits against maternal need and Prograf alcohol content with the specialist team.
References
- U.S. National Library of Medicine. PROGRAF (tacrolimus) capsules, injection, and granules — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b
- U.S. Food and Drug Administration. Prograf (tacrolimus) prescribing information label PDF.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f15b043d-fcfa-4ade-a3da-76700c0c5c2a
- U.S. National Library of Medicine. Tacrolimus capsule — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=759cf905-7406-4d1b-a1a8-10068cb11f04
- Drugs and Lactation Database (LactMed). Tacrolimus. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501104/
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.